Global Lysosomal Storage Diseases Market 2017-2021

Overview of the global lysosomal storage diseases market

There is a rising need for efficacious therapeutics that can either slow or reverse the progression of the lysosomal storage disease (LSD). The available medicines in the market are ineffective to improve neurological symptoms associated with LSDs due to the limited penetration of blood brain barrier. Technavio’s market study identifies this unmet need for effective treatment as one of the primary growth factors for the lysosomal storage diseases market. In addition to this, the high cost of treatment will also contribute to the growth of the market. Our market research analysts estimate that this market will grow steadily at a CAGR of more than 7% by 2021.

Get A Free Sample 

Lysosomal storage diseases market trends

Several legislative changes are aimed to promote research and development activities for rare diseases in the developing economies. Increasing awareness of the importance of orphan drug designations in these developing regions is encouraging the development of regulatory protocols. Pharmaceutical manufacturers in the developing countries are also focusing extensively on the research and development of novel therapeutics. This industry research report identifies the increase in regulatory assistance in emerging nations as one of the key trends that will contribute to the growth of the lysosomal storage diseases market.

Lysosomal storage diseases market forecast: Competitive landscape and key vendors

The lysosomal storage diseases market is highly consolidated due to the presence of a few key vendors who account for the major market share. The key vendors compete intensely based on factors such as product pipeline, emerging indications/applications, and collaborations. The competition among the vendors in the lysosomal diseases market will intensify in the coming years due to product portfolio expansions and the development of novel therapeutics using emerging technologies.

The leading vendors in the lysosomal storage diseases market

• Actelion Pharmaceuticals
• BioMarin
• Genzyme
• Shire

Lysosomal storage diseases market segmentation by therapy

• Enzyme replacement therapy​ (ERT)
• Substrate reduction therapy (SRT)
• Cystine depleting agents

End users primarily prefer enzyme replacement therapy (ERT) therapy as ERT contains targeted therapies that are efficient and effective for treating LSDs. Additionally, ERT also provides high efficacy and is administered through intravenous infusion where they metabolize the accumulated substrate effectively.

Lysosomal storage diseases market as per regions 

• Americas
• APAC
• EMEA

In EMEA, the rising awareness about the treatment of rare diseases, government initiatives to encourage orphan drug development, and favorable regulatory policies contribute to the growth of the lysosomal storage diseases market. Additionally, the availability of favorable reimbursement policies in Europe will also contribute to the growth of the lysosomal diseases market in the region.

Want a bigger picture? Try a FREE sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.   

Key questions answered in the report include

• What will the lysosomal storage diseases marke size and the growth rate be in 2021?
• What are the key factors driving the global lysosomal storage diseases market?
• What are the key lysosomal storage diseases marke trends impacting the growth of the market?
• What are the challenges to market growth?
• Who are the key vendors in the global lysosomal storage diseases market?
• What are the market opportunities and threats faced by the vendors in the global lysosomal storage diseases market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global lysosomal storage diseases market?

Technavio also offers customization on reports based on specific client requirement.